Domenico Mattoscio

Dr. Domenico Mattoscio

University of G. d'Annunzio Chieti and Pescara, Chieti, Italy
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2012 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
BRB. Rocca
B. Rocca
Francesca SantilliFrancesca Santilli
Francesca Santilli
DPD. Pitocco
D. Pitocco
LML. Mucci
L. Mucci
GPGiovanna Petrucci
Giovanna Petrucci
CPC. Patrono
C. Patrono

1 January 2018 in Mucosal Immunology
Verified
Journal Article
Closed access
MCM Codagnone
M Codagnone
ECE Cianci
E Cianci
ALAlessia Lamolinara
Alessia Lamolinara
VMV C Mari
V C Mari
ANA Nespoli
A Nespoli
ARA Recchiuti
A Recchiuti

4 February 2010 in Blood
Verified
Journal Article
Closed access
PDF file
ADAlfredo Dragani
Alfredo Dragani
SPSilvia Pascale
Silvia Pascale
Antonio RecchiutiAntonio Recchiuti
Antonio Recchiuti
Domenico MattoscioDomenico Mattoscio
Domenico Mattoscio
SLStefano Lattanzio
Stefano Lattanzio
BRBianca Rocca
Bianca Rocca
We tested whether cyclooxygenase 2 (COX-2) expression and unacetylated COX-1 in newly formed platelets might contribute to persistent thromboxane (TX) biosynthesis in aspirin-treated essential thrombocythemia (ET). Forty-one patients on chronic aspirin (100 mg/day) and 24 healthy subjects were studied. Platelet COX-2 expression was significantly increased in patients and correlated with thiazole orange–positive platelets (r = 0.71, P < .001). The rate of TXA2 biosynthesis in vivo, as reflected by urinary 11-dehydro-TXB2 (TXM) excretion, and the maximal biosynthetic capacity of platelets, as reflected by serum TXB2, were higher in patients compared with aspirin-treated healthy volunteers. Serum TXB2 was significantly reduced by the selective COX-2 inhibitor NS-398 added in vitro. Patients were randomized to adding the selective COX-2 inhibitor, etoricoxib, or continuing aspirin for 7 days. Etoricoxib significantly reduced by approximately 25% TXM excretion and serum TXB2. Fourteen of the 41 patients were studied again 21 (± 7) months after the first visit. Serum TXB2 was consistently reduced by approximately 30% by adding NS398 in vitro, while it was completely suppressed with 50μM aspirin. Accelerated platelet regeneration in most aspirin-treated ET patients may explain aspirin-persistent TXA2 biosynthesis through enhanced COX-2 activity and faster renewal of unacetylated COX-1. These findings may help in reassessing the optimal antiplatelet strategy in ET.

Verified
Journal Article
Open access
PDF file
Domenico MattoscioDomenico Mattoscio
Domenico Mattoscio
Alessandro MeddaAlessandro Medda
Alessandro Medda
SCSusanna Chiocca
Susanna Chiocca
Human papilloma viruses (HPVs) are a group of double-stranded DNA viruses known to be the primary cause of cervical cancer. In addition, evidence has now established their role in non-melanoma skin cancers, head and neck cancer (HNC), and the development of other anogenital malignancies. The prevalence of HPV-related HNC, in particular oropharyngeal cancers, is rapidly increasing, foreseeing that HPV-positive oropharyngeal cancers will outnumber uterine cervical cancers in the next 15–20 years. Therefore, despite the successful advent of vaccines originally licensed for cervical cancer prevention, HPV burden is still very high, and a better understanding of HPV biology is urgently needed. Autophagy is the physiological cellular route that accounts for removal, degradation, and recycling of damaged organelles, proteins, and lipids in lysosomal vacuoles. In addition to this scavenger function, autophagy plays a fundamental role during viral infections and cancers and is, therefore, frequently exploited by viruses to their own benefit. Recently, a link between HPV and autophagy has clearly emerged, leading to the conceivable development of novel anti-viral strategies aimed at restraining HPV infectivity. Here, recent findings on how oncogenic HPV16 usurp autophagy are described, highlighting similarities and differences with mechanisms adopted by other oncoviruses.

8 June 2010 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
Domenico MattoscioDomenico Mattoscio
Domenico Mattoscio
VEVirgilio Evangelista
Virgilio Evangelista
RCRaimondo De Cristofaro
Raimondo De Cristofaro
Antonio RecchiutiAntonio Recchiuti
Antonio Recchiuti
Assunta PandolfiAssunta Pandolfi
Assunta Pandolfi
MRMario Romano
Mario Romano
Inflammatory lung disease is a primary cause of morbidity and mortality in cystic fibrosis (CF). Mechanisms of unresolved acute inflammation in CF are not completely known, although the involvement of cystic fibrosis transmembrane conductance regulator (CFTR) in nonrespiratory cells is emerging. Here we examined CFTR expression and function in human platelets (PLTs) and found that they express a biologically active CFTR. CFTR blockade gave an ∼50% reduction in lipoxin A4 (LXA4) formation during PLT/polymorphonuclear leukocytes (PMN) coincubations by inhibiting the lipoxin synthase activity of PLT 12‐lipoxygenase. PLTs from CF patients generated ∼40% less LXA 4 compared to healthy subject PLTs. CFTR inhibition increased PLT‐dependent PMN viability (33.0±5.7 vs . 61.2±8.2%; P =0.033), suppressed nitric oxide generation (0.23±0.04 vs . 0.11±0.002 pmol/10 8 PLTs; P = 0.004), while reducing AKT (1.02±0.12 vs . 0.71±0.007 U; P =0.04), and increasing p38 MAPK phosphorylation (0.650±0.09 vs . 1.04±0.24 U; P =0.03). Taken together, these findings indicate that PLTs from CF patients are affected by the molecular defect of CFTR. Moreover, this CF PLT abnormality may explain the failure of resolution in CF.—Mattoscio, D., Evangelista, V., De Cristofaro, R., Recchiuti, A., Pandolfi, A., Di Silvestre, S., Manarini, S., Martelli, N., Rocca, B., Petrucci, B., Angelini, D.F., Battistini, L., Robuffo, I., Pensabene, T., Pieroni, L., Furnari, M.L., Pardo, F., Quattrucci, S., Lancellotti, S., Davi, G., Romano, M. Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response. FASEB J. 24, 3970–3980 (2010). www.fasebj.org

28 April 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
EIElisa Isopi
Elisa Isopi
Domenico MattoscioDomenico Mattoscio
Domenico Mattoscio
MCMarilina Codagnone
Marilina Codagnone
VMVeronica Cecilia Mari
Veronica Cecilia Mari
ALAlessia Lamolinara
Alessia Lamolinara
Antonio RecchiutiAntonio Recchiuti
Antonio Recchiuti
Non-resolving lung inflammation and Pseudomonas aeruginosa infections are the underlying cause of morbidity and mortality in cystic fibrosis (CF). The endogenous lipid mediator resolvin (Rv) D1 is a potent regulator of resolution, and its roles, actions, and therapeutic potential in CF are of interest. Here, we investigated actions and efficacy of RvD1 in preclinical models of cystic fibrosis. Cftr knockout mice with chronic P. aeruginosa lung infection were treated with RvD1 to assess differences in lung bacterial load, inflammation, and tissue damage. Cells from volunteers with CF were treated with RvD1 during ex vivo infection with P. aeruginosa, and effects on phagocytosis and inflammatory signaling were determined. In CF mice, RvD1 reduced bacterial burden, neutrophil infiltration, and histological signs of lung pathology, improving clinical scores of diseases. Mechanistically, RvD1 increased macrophage-mediated bacterial and leukocyte clearance in vivo. The clinical significance of these findings is supported by actions in primary leukocytes and epithelial cells from volunteers with CF where RvD1 enhanced P. aeruginosa phagocytosis and reduced genes and proteins associated to NF-κB activation and leukocyte infiltration. Concentration of RvD1 in sputum from patients with CF was also inversely correlated to those of cytokines and chemokines involved in CF lung pathology. These findings demonstrate efficacy of RvD1 in enhancing resolution of lung inflammation and infections and provide proof of concept for its potential as a prototypic novel pro-resolutive therapeutic approach for CF.